Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 724.63M | 768.50M | 661.54M | 633.67M | 683.03M | 783.03M |
Gross Profit | 128.40M | 112.69M | 98.25M | 127.92M | 180.42M | 291.38M |
EBITDA | -1.29B | -1.16B | -1.33B | -1.17B | -718.52M | -672.89M |
Net Income | -1.41B | -1.28B | -1.44B | -1.25B | -843.39M | -842.01M |
Balance Sheet | ||||||
Total Assets | 6.35B | 5.70B | 5.63B | 6.08B | 5.38B | 5.25B |
Cash, Cash Equivalents and Short-Term Investments | 5.03B | 4.65B | 4.40B | 4.50B | 4.10B | 3.64B |
Total Debt | 91.32M | 781.00K | 2.31M | 4.30M | 7.69M | 16.46M |
Total Liabilities | 548.63M | 509.27M | 590.20M | 566.14M | 474.95M | 442.99M |
Stockholders Equity | 5.80B | 5.19B | 5.04B | 5.51B | 4.90B | 4.81B |
Cash Flow | ||||||
Free Cash Flow | 211.20M | -1.33B | -1.35B | -1.20B | -1.01B | -653.01M |
Operating Cash Flow | 211.20M | -1.27B | -1.26B | -1.16B | -974.70M | -632.92M |
Investing Cash Flow | 0.00 | 65.14M | 3.27M | -20.23M | 344.25M | 86.20M |
Financing Cash Flow | 0.00 | 1.46B | 1.16B | 1.58B | 1.08B | 2.79B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | ¥10.06B | ― | ― | -0.97% | 1.19% | ||
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
― | €63.32M | ― | -31.29% | ― | ― | ― | |
55 Neutral | ¥13.20B | 41.11 | ― | 120.34% | ― | ||
44 Neutral | ¥16.90B | ― | ― | -9.04% | 2.12% | ||
― | ¥7.41B | ― | ― | ― | ― | ||
41 Neutral | ¥8.09B | ― | ― | -96.99% | 29.33% |
MEDINET Co., Ltd. reported a decrease in net sales by 17.7% for the first quarter ending December 2024, with a net loss of 345 million yen, indicating financial challenges. Despite a high capital adequacy ratio of 91%, the company did not declare any dividends, highlighting a cautious financial approach amidst declining profits.